• 1
    Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 741519.
  • 2
    Miyoshi I, Kubonishi I, Yoshimoto S et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294: 7701.
  • 3
    Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 48192.
  • 4
    Rodgers PE. The clinical features and aetiology of the neuropathic syndrome in Jamaica. West Indian Med J 1965; 14: 3647.
  • 5
    Osame M, Usuku K, Izumo S et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 10312.
  • 6
    Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 40710.
  • 7
    Yamada Y, Tomonaga M, Fukuda H et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 37582.
  • 8
    Marcais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Clinical trials of adult T-cell leukaemia/lymphoma treatment. Leuk Res Treatment 2012; 2012: 932175.
  • 9
    Goto K, Saeki K, Kurita M, Ohno S. HTLV-I associated uveitis in central Japan. Br J Ophthalmol 1995; 79: 101820.
  • 10
    Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol 2003; 7: 33661.
  • 11
    Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 20315.
  • 12
    Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982; 218: 5713.
  • 13
    Calattini S, Chevalier SA, Duprez R et al. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retrovirology 2005; 2: 30.
  • 14
    Wolfe ND, Heneine W, Carr JK et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci USA 2005; 102: 79949.
  • 15
    Inaba S, Sato H, Okochi K et al. Prevention of transmission of human T-lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus. One-year experience. Transfusion 1989; 29: 711.
  • 16
    Hino S, Yamaguchi K, Katamine S et al. Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res 1985; 76: 47480.
  • 17
    Bartholomew C, Saxinger WC, Clark JW et al. Transmission of HTLV-I and HIV among homosexual men in Trinidad. J Am Med Assoc 1987; 257: 26048.
  • 18
    Page JB, Lai SH, Chitwood DD, Klimas NG, Smith PC, Fletcher MA. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 1990; 335: 143941.
  • 19
    Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA 1983; 80: 361822.
  • 20
    Journo C, Douceron E, Mahieux R. HTLV gene regulation: because size matters, transcription is not enough. Future Microbiol 2009; 4: 42540.
  • 21
    Sodroski JG, Rosen CA, Haseltine WA. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 1984; 225: 3815.
  • 22
    Larocca D, Chao LA, Seto MH, Brunck TK. Human T-cell leukemia virus minus strand transcription in infected T-cells. Biochem Biophys Res Commun 1989; 163: 100613.
  • 23
    Koralnik IJ, Fullen J, Franchini G. The p12I, p13II, and p30II proteins encoded by human T-cell leukemia/lymphotropic virus type I open reading frames I and II are localized in three different cellular compartments. J Virol 1993; 67: 23606.
  • 24
    Inoue J, Seiki M, Yoshida M. The second pX product p27 chi-III of HTLV-1 is required for gag gene expression. FEBS Lett 1986; 209: 18790.
  • 25
    Fukumoto R, Andresen V, Bialuk I et al. In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. Blood 2009; 113: 372634.
  • 26
    Pique C, Ureta-Vidal A, Gessain A et al. Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides. J Exp Med 2000; 191: 56772.
  • 27
    Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66: 228895.
  • 28
    Feuer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 2005; 24: 59966004.
  • 29
    Yamamoto N, Okada M, Koyanagi Y, Kannagi M, Hinuma Y. Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science 1982; 217: 7379.
  • 30
    Chen IS, Quan SG, Golde DW. Human T-cell leukemia virus type II transforms normal human lymphocytes. Proc Natl Acad Sci USA 1983; 80: 70069.
  • 31
    Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 2001; 98: 185861.
  • 32
    Jones KS, Fugo K, Petrow-Sadowski C et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol 2006; 80: 8291302.
  • 33
    Murphy EL, Fridey J, Smith JW et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology 1997; 48: 31520.
  • 34
    Bangham CR. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 2003; 84: 317789.
  • 35
    Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006; 103: 7205.
  • 36
    Nagai M, Usuku K, Matsumoto W et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4: 58693.
  • 37
    Nicot C, Mulloy JC, Ferrari MG et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 2001; 98: 8239.
  • 38
    Johnson JM, Nicot C, Fullen J et al. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J Virol 2001; 75: 608694.
  • 39
    Fukumoto R, Dundr M, Nicot C et al. Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1. J Virol 2007; 81: 908899.
  • 40
    Ding W, Albrecht B, Kelley RE et al. Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells. J Virol 2002; 76: 1037482.
  • 41
    Franchini G, Mulloy JC, Koralnik IJ et al. The human T-cell leukemia/lymphotropic virus type I p12I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16-kilodalton subunit of the vacuolar H+ ATPase. J Virol 1993; 67: 77014.
  • 42
    Albrecht B, D'Souza CD, Ding W, Tridandapani S, Coggeshall KM, Lairmore MD. Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I). J Virol 2002; 76: 3493501.
  • 43
    Van Prooyen N, Gold H, Andresen V et al. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc Natl Acad Sci USA 2010; 107: 2073843.
  • 44
    Johnson JM, Mulloy JC, Ciminale V, Fullen J, Nicot C, Franchini G. The MHC class I heavy chain is a common target of the small proteins encoded by the 3′ end of HTLV type 1 and HTLV type 2. AIDS Res Hum Retroviruses 2000; 16: 177781.
  • 45
    Tsukahara T, Ratner L. Substitution of HIV Type 1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses 2004; 20: 93843.
  • 46
    Nicot C, Dundr M, Johnson JM et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004; 10: 197201.
  • 47
    Younis I, Khair L, Dundr M, Lairmore MD, Franchini G, Green PL. Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator. J Virol 2004; 78: 1107783.
  • 48
    Baydoun HH, Pancewicz J, Nicot C. Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair. Blood 2011; 117: 5897906.
  • 49
    D'Agostino DM, Zotti L, Ferro T et al. Expression and functional properties of proteins encoded in the x-II ORF of HTLV-I. Virus Res 2001; 78: 3543.
  • 50
    Andresen V, Pise-Masison CA, Sinha-Datta U et al. Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles. Blood 2011; 118: 154959.
  • 51
    Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002; 76: 1281322.
  • 52
    Cavanagh MH, Landry S, Audet B et al. HTLV-I antisense transcripts initiating in the 3′LTR are alternatively spliced and polyadenylated. Retrovirology 2006; 3: 15.
  • 53
    Murata K, Hayashibara T, Sugahara K et al. A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization. J Virol 2006; 80: 2495505.
  • 54
    Koiwa T, Hamano-Usami A, Ishida T et al. 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol 2002; 76: 938997.
  • 55
    Halin M, Douceron E, Clerc I et al. Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood 2009; 114: 242738.
  • 56
    Sprent J, Tough DF. Lymphocyte life-span and memory. Science 1994; 265: 1395400.
  • 57
    Grassmann R, Berchtold S, Radant I et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992; 6: 45705.
  • 58
    Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19: 47596.
  • 59
    Teshigawara K, Maeda M, Nishino K et al. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol 1985; 2: 1726.
  • 60
    Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J 1986; 5: 28838.
  • 61
    Hanon E, Goon P, Taylor GP et al. High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. Blood 2001; 98: 7216.
  • 62
    Greene WC, Leonard WJ, Wano Y et al. Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Science 1986; 232: 87780.
  • 63
    Niinuma A, Higuchi M, Takahashi M et al. Aberrant activation of the interleukin-2 autocrine loop through the nuclear factor of activated T cells by nonleukemogenic human T-cell leukemia virus type 2 but not by leukemogenic type 1 virus. J Virol 2005; 79: 1192534.
  • 64
    Albrecht B, Collins ND, Burniston MT et al. Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 2000; 74: 982835.
  • 65
    Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood 1998; 91: 47017.
  • 66
    Valeri VW, Hryniewicz A, Andresen V et al. Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits. Blood 2010; 116: 380917.
  • 67
    Hiraragi H, Kim SJ, Phipps AJ et al. Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13(II) is required for viral infectivity in vivo. J Virol 2006; 80: 346976.
  • 68
    Ye J, Silverman L, Lairmore MD, Green PL. HTLV-1 Rex is required for viral spread and persistence in vivo but is dispensable for cellular immortalization in vitro. Blood 2003; 102: 39639.
  • 69
    Arnold J, Yamamoto B, Li M et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 2006; 107: 397682.